Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng L L, Chan W Y, Wo N C, Sawyer W H
Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699-0008.
J Med Chem. 1992 Oct 16;35(21):3895-904. doi: 10.1021/jm00099a018.
We report the solid-phase synthesis and antagonistic potencies of 25 analogues (1-25) of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-O-ethyl-D-tyrosine,4-valine]arginine-vasopressin (d(CH2)5D-Tyr(Et)2-VAVP) (A) and of the related Ile4 (D) and [D-Phe2,Ile4] (E) analogues, potent antagonists of the antidiuretic (V2-receptor) and of the vasopressor (V1a-receptor) responses to arginine-vasopressin (AVP). Six of these peptides (1, 13, 17, 19, 21, and 23) have the Pro-Arg-Gly-NH2 tripeptide side chain fully or partially replaced or extended by ethylenediamine (Eda). The remaining 19 peptides have L- or D-amino acids retrolinked to these six C-terminal Eda peptides. Peptides 1, 13, 17, and 19 all have the ring structure of (A). Their side-chain structures are as follows: 1, Eda; 13, Pro-Eda; 17, Pro-Arg-Eda; 19, Arg-Gly-Eda. Peptide 21 is the Pro-Arg-Eda analogue of D; peptide 23 is the Pro-Arg-Gly-Eda analogue of E. Peptide 2 is the retro-Arg analogue of 1. Its side-chain structure is Eda<--Arg. Peptides 3-6 are analogues of 2 which have the D-Tyr-(Et)2 residue replaced by L-Tyr(Et)2 (3), D-Phe2 (4), D-Ile2 (5), or D-Leu2 (6), respectively. Peptides 7-12 are analogues of 2 which have the C-terminal retro-Arg replaced in retrofashion by D-Arg (7), Gly (8), Orn (9), D-Orn (10), D-Lys (11), or Arg-Arg (12). Peptides 14-16 have D-Orn (14), D-Lys (15), and D-Arg (16) retrosubstituted to peptide 13. Peptides 18, 20, and 22 are the retro-Arg-substituted analogues of 17, 19, and 21, respectively. Peptides 24 and 25 have Val and D-Val in retrolinkage with 23, respectively. All 25 peptides were examined for agonistic and antagonistic potencies in AVP V2/V1a assays. With the exception of peptides 5 and 6, all exhibit potent anti-V1a antagonism, with anti-V1a pA2 values in the range 7.64-8.33.(ABSTRACT TRUNCATED AT 400 WORDS)
我们报道了[1-(β-巯基-β,β-五亚甲基丙酸),2-O-乙基-D-酪氨酸,4-缬氨酸]精氨酸加压素(d(CH2)5D-Tyr(Et)2-VAVP)(A)及其相关的Ile4(D)和D-Phe2,Ile4类似物的25种类似物(1-25)的固相合成及拮抗效力,这些类似物是抗利尿(血管加压素V2受体)和升压(血管加压素V1a受体)对精氨酸加压素(AVP)反应的强效拮抗剂。其中6种肽(1、13、17、19、21和23)的Pro-Arg-Gly-NH2三肽侧链被乙二胺(Eda)完全或部分取代或延长。其余19种肽具有与这6种C末端Eda肽反向连接的L-或D-氨基酸。肽1、13、17和19均具有(A)的环结构。它们的侧链结构如下:1为Eda;13为Pro-Eda;17为Pro-Arg-Eda;19为Arg-Gly-Eda。肽21是D的Pro-Arg-Eda类似物;肽23是E的Pro-Arg-Gly-Eda类似物。肽2是1的反向Arg类似物。其侧链结构为Eda<--Arg。肽3-6是2的类似物,分别将D-Tyr-(Et)2残基替换为L-Tyr(Et)2(3)、D-Phe2(4)、D-Ile2(5)或D-Leu2(6)。肽7-12是2的类似物,其C末端反向Arg被D-Arg(7)、Gly(8)、Orn(9)、D-Orn(10)、D-Lys(11)或Arg-Arg(12)反向取代。肽14-16将D-Orn(14)、D-Lys(15)和D-Arg(16)反向取代到肽13上。肽18、20和22分别是17、19和21的反向Arg取代类似物。肽24和25分别将Val和D-Val与23反向连接。在AVP V2/V1a试验中检测了所有25种肽的激动和拮抗效力。除肽5和6外,所有肽均表现出强效的抗V1a拮抗作用,抗V1a pA2值在7.64-8.33范围内。(摘要截断于400字)